期刊文献+
共找到10篇文章
< 1 >
每页显示 20 50 100
Prolonged intermittent theta burst stimulation restores the balance between A_(2A)R-and A_(1)R-mediated adenosine signaling in the 6-hydroxidopamine model of Parkinson's disease
1
作者 Milica Zeljkovic Jovanovic Jelena Stanojevic +4 位作者 Ivana Stevanovic Milica Ninkovic Tihomir V.Ilic Nadezda Nedeljkovic Milorad Dragic 《Neural Regeneration Research》 SCIE CAS 2025年第7期2053-2067,共15页
An imbalance in adenosine-mediated signaling,particularly the increased A_(2A)R-mediated signaling,plays a role in the pathogenesis of Parkinson's disease.Existing therapeutic approaches fail to alter disease prog... An imbalance in adenosine-mediated signaling,particularly the increased A_(2A)R-mediated signaling,plays a role in the pathogenesis of Parkinson's disease.Existing therapeutic approaches fail to alter disease progression,demonstrating the need for novel approaches in PD.Repetitive transcranial magnetic stimulation is a non-invasive approach that has been shown to improve motor and non-motor symptoms of Parkinson's disease.However,the underlying mechanisms of the beneficial effects of repetitive transcranial magnetic stimulation remain unknown.The purpose of this study is to investigate the extent to which the beneficial effects of prolonged intermittent theta burst stimulation in the 6-hydroxydopamine model of experimental parkinsonism are based on modulation of adenosine-mediated signaling.Animals with unilateral 6-hydroxydopamine lesions underwent intermittent theta burst stimulation for 3 weeks and were tested for motor skills using the Rotarod test.Immunoblot,quantitative reverse transcription polymerase chain reaction,immunohistochemistry,and biochemical analysis of components of adenosine-mediated signaling were performed on the synaptosomal fraction of the lesioned caudate putamen.Prolonged intermittent theta burst stimulation improved motor symptoms in 6-hydroxydopamine-lesioned animals.A 6-hydroxydopamine lesion resulted in progressive loss of dopaminergic neurons in the caudate putamen.Treatment with intermittent theta burst stimulation began 7 days after the lesion,coinciding with the onset of motor symptoms.After treatment with prolonged intermittent theta burst stimulation,complete motor recovery was observed.This improvement was accompanied by downregulation of the e N/CD73-A_(2A)R pathway and a return to physiological levels of A_(1)R-adenosine deaminase 1 after 3 weeks of intermittent theta burst stimulation.Our results demonstrated that 6-hydroxydopamine-induced degeneration reduced the expression of A_(1)R and elevated the expression of A_(2A)R.Intermittent theta burst stimulation reversed these effects by restoring the abundances of A_(1)R and A_(2A)R to control levels.The shift in ARs expression likely restored the balance between dopamine-adenosine signaling,ultimately leading to the recovery of motor control. 展开更多
关键词 a_(1)r a_(2a)r adenosine receptors aDENOSINE ecto-5′-nucleotidase intermittent theta burst stimulation non-invasive brain stimulation Parkinson's disease purinergic signalling
下载PDF
CONTROL OF ANGIOGENESIS BY INHIBITOR OF PHOSPHOLIPASE A_2
2
作者 陈文明 李利红 +4 位作者 朱嘉芷 刘晋玮 Soria Jeannette Soria Claudine Yedgar Saul 《Chinese Medical Sciences Journal》 CAS CSCD 2004年第1期6-12,共7页
Objective To investigate the potential effects of angiogenic process by secretory phospholipase A2 (sPLA2)inhibitor-HyPE(linking N-derivatized phosphatidyl-ethanolamine to hyaluronic acid)on human bone marrow endothel... Objective To investigate the potential effects of angiogenic process by secretory phospholipase A2 (sPLA2)inhibitor-HyPE(linking N-derivatized phosphatidyl-ethanolamine to hyaluronic acid)on human bone marrow endothelial cell line(HBME-1). Methods In order to examine the suppressing effects of HyPE on HBME-1 proliferation, migration, and capillary-like tube formation, HBME-1 were activated by angiogenic factor, specifically by basic fibroblast growth factor(b-FGF), vascular endothelial growth factor(VEGF),and oncostatin M(OSM)(at a final concentration of 25, 20, and 2.5 ng/mL, respectively), then HBME-1 proliferation, migration, and tube forma-tion were studied in the absence or presence of HyPE. HBME-1 tube formation was specially analyzed in fibrin gel. Results HyPE effectively inhibited HBME-1 proliferation and migration as a dose-dependent manner, whatever HBME-1 were grown in the control culture medium or stimulated with b-FGF, VEGF, or OSM. In fibrin, the formations of HBME-1 derived tube-like structures were enhanced by all angiogenic factors, but these were strongly suppressed by HyPE. Conclusions The results support the involvement of sPLA2 in angiogenesis. It is proposed that sPLA2 inhibitor introduces a novel approach in the control of cancer development. 展开更多
关键词 aNGIOGENESIS phospholipase a_2 inhibitor endothelial cell line
下载PDF
Regulatory effects of phospholipase A_2 inhibitors on platelet activating factor in endotoxic shock in rabbits
3
作者 杜文华 李著 +1 位作者 陆松敏 陈惠荪 《Journal of Medical Colleges of PLA(China)》 CAS 1996年第2期135-138,共4页
The regulatory effects of phospholipase A2(PLA2) inhibitors, chloroquine and dexamethasone, on the activity of blood PLA2 and its related lipid mediators during endotoxic shock were observed in rabbits. The rabbits we... The regulatory effects of phospholipase A2(PLA2) inhibitors, chloroquine and dexamethasone, on the activity of blood PLA2 and its related lipid mediators during endotoxic shock were observed in rabbits. The rabbits were randomized into 4 groups as follows : The normal control (NC) group consisted of 12 rabbits with sham injection . the endotoxic shork (ES) group of 31 rabbits, the chloquine pretreated (CQ) group of 16 rabbits receiving 3 mg/kg of chlorqouine and the dexamethasone-pretreated (DM) group of 10 rabbits receiving 5 mg/kg of dexamethasone. Blood was sampled before and 5 and 30 min, 1 ,3, 5 and 8 h after the administration of endotoxin for the determination of PLA2, platelet activating factor (PAF) , TXB2 and 6-keto-PGF1α. In addrtion, changes of mean arterial pressure (MAP) and respiratory rate (RR) were also carefully recorded. It was found that the activities of PLA2 and PAF and the levels of TXB2 and 6-keto-PGF1α. were significantly increased after the infusion of endotoxin. CQ and DM markedly suppressed the activities of PLA2 and PAF. The inhibition of CQ on TXB2 and 6-keto-PGF1α was greater than that of DM. Besides, CQ and DM could increase the survival rate of the animals from 48% to 75% (CQ group) and 70% (DM group). These findings suggest that PLA2 inhibitors such as CQ and DM can significantly attenuate the formation of shock mediators such as PLA2, PAF, TXB2 and 6-keto-PGF1α, and so improve the prognosis of the victims of endotoxic shock. 展开更多
关键词 phospholipase a_2 inhibitor platelet-activating factor endotoxic shock raBBITS
下载PDF
Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19:A review
4
作者 Bhagat Singh Dheer Singh +2 位作者 Vinod Verma Ramakant Yadav Raj Kumar 《Journal of Pharmaceutical Analysis》 SCIE CAS CSCD 2022年第2期215-220,共6页
As of August 16,2021,there have been 207,173,086 confirmed cases and 4,361,996 deaths due to the coronavirus disease(COVID-19),and the pandemic remains a global challenge.To date,no effective and approved drugs are av... As of August 16,2021,there have been 207,173,086 confirmed cases and 4,361,996 deaths due to the coronavirus disease(COVID-19),and the pandemic remains a global challenge.To date,no effective and approved drugs are available for the treatment of COVID-19.Angiotensin-converting enzyme 2(ACE2)plays a crucial role in the invasion into host cells by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the etiological agent of COVID-19.Notably,ACE2 density is influenced by medical conditions,such as hypertension,or by drugs,including angiotensin-converting enzyme inhibitors(ACEIs)and angiotensin receptor blockers(ARBs),which can change the fate of SARS-CoV-2 infectivity.ACE2 is a target for these drugs and can be manipulated to limit the viral entry and replication within the cells.Different strategies aimed at blocking ACE2 with small molecules,peptides,and antibodies,or by neutralizing the virus through its competitive binding with human recombinant soluble ACE2(hrsACE2)are currently under investigation.In this article,we review the current state of knowledge that emphasizes the need to find effective therapeutic agents against COVID-19 by exploiting ACE2 as a potential target.The increased soluble ACE2 levels and the application of hrsACE2 in patients with COVID-19 can be implemented to control the disease.It has not yet been established whether hypertension and other comorbidities,independent of age,have a direct role in COVID-19.Therefore,the use of renin-angiotensin system inhibitors,ACEIs and ARBs,should not be discontinued during COVID-19 treatment. 展开更多
关键词 COVID-19 aCE2 receptors hrsaCE2 aCE inhibitors raS aT1r blocker
下载PDF
AZD0914关键中间体(2R,6R)-2,6-二甲基吗啉的合成工艺研究
5
作者 雷响 张银勇 +3 位作者 张丹 赵文豪 孟昕 杨玉社 《合成化学》 CAS 2022年第12期937-944,共8页
(2 R,6 R)-2,6-二甲基吗啉(1)为合成新型细菌II型拓扑异构酶抑制剂AZD0194(Zoliflodacin)的关键中间体。本文以(S)-2-羟基丙酸乙酯(12)为原料,经三氟甲磺酰化、S_(N)2反应、硼氢化钠还原、对甲苯磺酰化、环合、成盐、催化氢解、游离和... (2 R,6 R)-2,6-二甲基吗啉(1)为合成新型细菌II型拓扑异构酶抑制剂AZD0194(Zoliflodacin)的关键中间体。本文以(S)-2-羟基丙酸乙酯(12)为原料,经三氟甲磺酰化、S_(N)2反应、硼氢化钠还原、对甲苯磺酰化、环合、成盐、催化氢解、游离和蒸馏提纯等步骤,成功合成了化合物1。经过对合成路线中反应条件及提纯方法的优化,以6步反应且总收率为32%获得化合物1。 展开更多
关键词 拓扑异构酶抑制 aZD0914 关键中间体 (2r 6r)-2 6-二甲基吗啉 工艺改进 合成
下载PDF
Zeste基因增强子同源物2抑制剂减轻氧糖剥夺/再灌注诱导的神经元氧化应激和铁死亡 被引量:2
6
作者 柳亚珍 孙海伟 +4 位作者 汪继 朱建良 马丽梅 肖盐 刘励军 《中国急救医学》 CAS CSCD 2023年第6期472-480,共9页
目的探讨Zeste基因增强子同源物2(EZH2)抑制剂GSK126在神经元缺血-再灌注损伤中的作用及机制。方法采用海马神经元HT22细胞制备氧糖剥夺/再灌注(OGD/R)模型。细胞分为正常对照组(Control组)、OGD/R模型组(OGD/R组)和OGD/R模型+低、中、... 目的探讨Zeste基因增强子同源物2(EZH2)抑制剂GSK126在神经元缺血-再灌注损伤中的作用及机制。方法采用海马神经元HT22细胞制备氧糖剥夺/再灌注(OGD/R)模型。细胞分为正常对照组(Control组)、OGD/R模型组(OGD/R组)和OGD/R模型+低、中、高浓度EZH2抑制剂组(OGD/R+GSK1260.5、1、5μmol/L组)。采用CCK-8法、流式细胞术检测各组HT22细胞损伤,相应试剂盒检测细胞氧化应激指标活性氧(ROS)水平、丙二醛(MDA)含量和谷胱甘肽/氧化型谷胱甘肽(GSH/GSSG)比值。通过荧光探针C11 BODIPY 581/591和FerroOrange检测细胞内铁死亡指标脂质过氧化物(Lipid ROS)和Fe^(2+)含量。实时荧光定量逆转录聚合酶链反应(RT-qPCR)和蛋白免疫印记法(Western blot)实验检测细胞EZH2、NRF2、HO-1、SLC7A11和GPX4的mRNA和蛋白表达。结果与Control组比较,OGD/R组HT22细胞活力降低,细胞死亡率升高,细胞内ROS水平升高,MDA含量增加,GSH/GSSG比值减少,Lipid ROS、Fe^(2+)含量增加,EZH2的mRNA和蛋白表达升高,NRF2、HO-1、SLC7A11和GPX4的mRNA和蛋白表达均降低(P值均<0.05)。与OGD/R组比较,OGD/R+GSK1260.5、1、5μmol/L组HT22细胞活力均升高,细胞死亡率均下降,细胞内ROS水平均下降,MDA含量均减少,GSH/GSSG比值均增加,Lipid ROS、Fe^(2+)含量均减少,EZH2的mRNA和蛋白表达均降低,NRF2、HO-1、SLC7A11和GPX4的mRNA和蛋白表达均升高(P值均<0.05)。结论EZH2抑制剂GSK126可减轻OGD/R诱导的神经元细胞损伤,其机制可能与NRF2/HO-1通路抑制氧化应激和SLC7A11/GPX4通路抑制铁死亡有关。 展开更多
关键词 Zeste基因增强子同源物2(EZH2) GSK126(EZH2抑制剂) 氧糖剥夺/再灌注(OGD/r) 铁死亡
下载PDF
靶向腺苷A_(2A)受体的肿瘤免疫治疗研究进展 被引量:1
7
作者 张芷菁 张启怡 +3 位作者 金祖翼 朱凯 丁文 张小雷 《药学学报》 CAS CSCD 北大核心 2022年第9期2557-2569,共13页
虽然免疫治疗现已成为对抗恶性肿瘤的革命性策略,但应答率不高,易产生耐受仍是制约肿瘤免疫治疗临床深入应用的瓶颈。不少研究表明,免疫抑制型肿瘤微环境和复杂的免疫逃逸机制是影响免疫检查点治疗效果和应答率的重要因素。因此,逆转肿... 虽然免疫治疗现已成为对抗恶性肿瘤的革命性策略,但应答率不高,易产生耐受仍是制约肿瘤免疫治疗临床深入应用的瓶颈。不少研究表明,免疫抑制型肿瘤微环境和复杂的免疫逃逸机制是影响免疫检查点治疗效果和应答率的重要因素。因此,逆转肿瘤微环境障碍是提高免疫治疗应答率的关键。在肿瘤微环境中,胞外腺苷高水平的积累对免疫应答的抑制作用受到人们越来越多的关注。靶向腺苷受体,尤其是A_(2A)R亚型,可能是激活免疫应答、提高免疫治疗效果的有效策略。靶向腺苷-A_(2A)R通路可以增加免疫浸润,增强免疫细胞功能,将对免疫治疗不敏感的“冷肿瘤”部分逆转为“热肿瘤”,以增强治疗应答率并提高当前免疫治疗的疗效。目前,有不少的腺苷受体抑制剂已经在临床试验中显示出良好的效果,特别是与免疫检查点抑制剂、化疗和获得性细胞疗法的药物联用,有望为肿瘤免疫治疗带来新的突破。本文综述了肿瘤微环境中腺苷积累的方式、腺苷A_(2A)受体的作用和调控机制、腺苷A_(2A)受体抑制剂的临床试验进展和用药策略、靶向腺苷A_(2A)受体的潜在风险及其应用前景。 展开更多
关键词 免疫治疗 肿瘤微环境 腺苷受体 a_(2a)r抑制剂 肿瘤免疫治疗药物
原文传递
全球抗糖尿病药物研发现状及市场分析 被引量:11
8
作者 阿丽塔 刘晓婷 《中国药房》 CAS CSCD 2013年第29期2689-2691,共3页
目的:为开发新一代抗糖尿病药物提供新的思路。方法:利用文献调研、网络调研、专家咨询等方法,系统整理和归纳了抗糖尿病药物的在研数量、抗2型糖尿病药物的主要研发公司及研发药物数量和2006-2010年抗糖尿病药物的市场销售额,分析目前... 目的:为开发新一代抗糖尿病药物提供新的思路。方法:利用文献调研、网络调研、专家咨询等方法,系统整理和归纳了抗糖尿病药物的在研数量、抗2型糖尿病药物的主要研发公司及研发药物数量和2006-2010年抗糖尿病药物的市场销售额,分析目前全球抗糖尿病药物的研发现状及不同种类药物的市场表现。结果与结论:截至2012年3月,共有400多种抗2型糖尿病药物处于临床试验阶段,默克公司研发的药物数量较多,其次为辉瑞、葛兰素史克、罗氏、礼来、诺和诺德等公司。2010年抗糖尿病药物全球销售额达344.29亿美元,比2009年304.06亿元的销售额增长了12.2%,比2006年213.10亿美元的销售额增长了68.2%。胰岛素和胰岛素类似物所占市场份额最高,且保持了逐年增长的趋势;口服药物中促胰岛素分泌剂市场保持了较高的增长势头;同时随着二肽基肽酶Ⅳ(DPP-Ⅳ)抑制剂、胰高血糖素样肽1(GLP-1)类似物等疗效更佳、副作用更小的新型口服促胰岛素分泌剂的上市,格列奈类药物的市场份额正在逐渐减小。DPP-Ⅳ抑制剂、GLP-1类似物、胰高血糖素受体拮抗药、钠-葡萄糖协同转运蛋白2抑制剂等为当下新一代抗2型糖尿病药物研究的重点。 展开更多
关键词 抗糖尿病药物 2型糖尿病 二肽基肽酶Ⅳ抑制剂 胰高血糖素样肽1类似物 胰高血糖素受体拮抗药 胰岛素 研发
原文传递
光学纯的2-羟基-4-苯基丁酸乙酯的合成进展 被引量:1
9
作者 诸吕锋 陈厚和 +3 位作者 孟庆华 谢小敏 李月刚 张兆国 《有机化学》 SCIE CAS CSCD 北大核心 2012年第4期641-650,共10页
(R)-2-羟基-4-苯基丁酸乙酯是血管紧张素转化酶抑制剂类(ACEI)药物的重要中间体.综述了其合成方法,重点介绍了最新的高效合成方法的研究进展.
关键词 (r)-2-羟基-4-苯基丁酸乙酯 血管紧张素转化酶抑制剂 不对称氢化
原文传递
脑胶质瘤中异柠檬酸脱氢酶突变及其抑制剂研究进展 被引量:1
10
作者 张娜 黄嘉骏 +4 位作者 林婉君 龙泽 黄晓明 杜晶晶 马文哲 《中国药学杂志》 CAS CSCD 北大核心 2019年第3期165-169,共5页
异柠檬酸脱氢酶突变存在于多数脑胶质瘤中,这是一种新的点突变,可导致原有的酶活性丧失,但却能催化α-酮戊二酸生成具有致癌作用的R-2-羟基戊二酸。异柠檬酸脱氢酶抑制剂能够减少R-2-羟基戊二酸的产生,诱导组蛋白去甲基化,从而抑制肿瘤... 异柠檬酸脱氢酶突变存在于多数脑胶质瘤中,这是一种新的点突变,可导致原有的酶活性丧失,但却能催化α-酮戊二酸生成具有致癌作用的R-2-羟基戊二酸。异柠檬酸脱氢酶抑制剂能够减少R-2-羟基戊二酸的产生,诱导组蛋白去甲基化,从而抑制肿瘤发展。从2012年,首个抑制剂被发现,异柠檬酸脱氢酶突变体抑制剂就成为脑胶质瘤治疗领域的研究重点。2017年8月和2018年7月,异柠檬酸脱氢酶2突变体抑制剂enasidenib(AG-221)和异柠檬酸脱氢酶1突变体抑制剂ivosidenib(AG-120)相继被FDA批准上市,用于急性髓细胞性白血病的治疗,证实了异柠檬酸脱氢酶突变体作为肿瘤治疗靶点的可靠性。目前全球多个医药机构都在进行异柠檬酸脱氢酶抑制剂的研发,笔者对现有异柠檬酸脱氢酶抑制剂的研究现状进行综述。 展开更多
关键词 脑胶质瘤 异柠檬酸脱氢酶突变 r-2-羟基戊二酸 异柠檬酸脱氢酶抑制剂
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部